[go: up one dir, main page]

AR044507A1 - Compuestos de quinolina y quinoxalina - Google Patents

Compuestos de quinolina y quinoxalina

Info

Publication number
AR044507A1
AR044507A1 ARP040101024A ARP040101024A AR044507A1 AR 044507 A1 AR044507 A1 AR 044507A1 AR P040101024 A ARP040101024 A AR P040101024A AR P040101024 A ARP040101024 A AR P040101024A AR 044507 A1 AR044507 A1 AR 044507A1
Authority
AR
Argentina
Prior art keywords
substituted
carbon
optionally
nitrogen
optionally mono
Prior art date
Application number
ARP040101024A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR044507A1 publication Critical patent/AR044507A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos de quinolina y quinoxalina, composiciones farmacéuticas que contienen tales compuestos y el uso de tales compuestos para aumentar ciertos niveles de lípidos en el plasma, incluyendo la lipoproteína de alta densidad del colesterol y para reducir otros niveles de lípidos en el plasma, tales como colesterol LDL y triglicéridos, y por consiguiente, para tratar enfermedades que se ven afectadas por los niveles bajos de colesterol HDL y/o niveles altos de colesterol LDL y triglicéridos, tales como ateroesclerosis y enfermedades cardiovasculares Reivindicación 1: Un compuesto de acuerdo con la fórmula (1) donde C3 es carbono; J es nitrógeno o carbono, donde si J es carbono, entonces el enlace entre C3 y J es un enlace sencillo o doble y si J es nitrógeno, entonces el enlace entre C3 y J es un enlace sencillo; R1 es Y, W-X o W-Y1; donde W es un carbonilo, tiocarbonilo, sulfinilo o sulfonilo; X es -O-Y, -S-Y, -N(H)-Y o -N-(Y)2; Y para cada caso es independientemente Z o una cadena carbonada totalmente saturada, parcialmente insaturada o totalmente insaturada de uno a diez miembros, lineal o ramificada donde cada carbono, distinto del carbono de unión, puede reemplazarse opcionalmente con uno o dos heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno y donde dicho carbono está opcionalmente mono-, di- o tri-substituido independientemente con halo, estando dicho carbono opcionalmente mono-substituido con hidroxi, estando dicho carbono opcionalmente substituido con oxo, estando dicho azufre opcionalmente mono- o di-substituido con oxo, estando dicho nitrógeno opcionalmente mono-, o di-substituido con oxo, y estando dicha cadena carbonada opcionalmente mono-substituida con Z; e Y1 para cada caso es independientemente Z o una cadena carbonada totalmente saturada, parcialmente insaturada o totalmente insaturada de uno a diez miembros, lineal o ramificada, donde cada carbono, distinto del carbono de unión, puede reemplazarse opcionalmente con uno o dos heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno y donde dicho carbono está opcionalmente mono-, di- o tri-substituido independientemente con halo, estando dicho carbono opcionalmente mono-substituido con hidroxi, estando dicho carbono opcionalmente mono-substituido con oxo, estando dicho azufre opcionalmente mono- o di-substituido con oxo, estando dicho nitrógeno opcionalmente mono-, o di-substituido con oxo, y estando dicha cadena carbonada opcionalmente mono-substituida con Z; donde Z es un anillo de tres a ocho miembros, parcialmente saturado, totalmente saturado o totalmente insaturado, que tiene opcionalmente de uno a cuatro heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno, o un anillo bicíclico que consta de dos anillos condensados de tres a seis miembros, parcialmente saturados, totalmente saturados o totalmente insaturados, tomados independientemente, que tienen opcionalmente de uno a cuatro heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno; y dicho substituyente Z está opcionalmente mono-, di- o tri-substituido independientemente con halo, alquenilo C2-6, alquilo C1-6, hidroxi, alcoxi C1-6, alquiltio C1-4, amino, nitro, ciano, oxo, carboxi, alquiloxicarbonilo C1-6, mono-N- o di-N,N-alquilamino C1-6 donde dicho substituyente alquilo C1-6 está opcionalmente mono-, di- o tri-substituido independientemente con halo, hidroxi, alcoxi C1-6, alquiltio C1-4, amino, nitro, ciano, oxo, carboxi, alquiloxicarbonilo C1-6, mono-N- o di-N,N-alquilamino C1-6, estando dicho substituyente alquilo C1-6 o alcoxi C1-6 opcionalmente substituido con uno a nueve átomos de flúor; R2 es una cadena carbonada, parcialmente saturada, totalmente saturada o totalmente insaturada de uno a seis miembros, lineal o ramificada, donde cada carbono, distinto del carbono de unión, puede reemplazarse opcionalmente con uno o dos heteroátomos seleccionados independientemente entre oxígeno y azufre, y donde dicho carbono está opcionalmente mono-, di- o tri-substituido independientemente con halo, estando dicha cadena carbonada opcionalmente mono-substituida con oxo, estando dicho carbono opcionalmente mono-substituido con hidroxi, estando dicho azufre opcionalmente mono- o di-substituido con oxo; o dicho R2 es un anillo parcialmente saturado, totalmente saturado o totalmente insaturado de tres a siete miembros, que tiene opcionalmente de uno a dos heteroátomos seleccionados independientemente entre oxígeno y azufre, donde dicho anillo R2 está opcionalmente unido mediante un alquilo C1-4; donde dicho anillo R2 está opcionalmente mono-, di- o tri-substituido independientemente con halo, alquenilo C2-6, alquilo C1-6, hidroxi, alcoxi C1-6, alquiltio C1-4, amino, nitro, ciano, oxo, carboxi, alquiloxicarbonilo, mono-N- o di-N,N-alquilamino C1-6 donde dicho substituyente alquilo C1-6 está opcionalmente mono- , di- o tri-substituido independientemente con halo, hidroxi, alcoxi C1-6, alquiltio C1-4, oxo o alquiloxicarbonilo C1-6; R3 es una cadena carbonada totalmente saturada, parcialmente insaturada o totalmente insaturada uno a seis miembros, lineal o ramificada, que contiene C4a, donde C4a es un átomo de carbono que conecta con J, donde cada carbono en la cadena carbonada puede reemplazarse opcionalmente con un heteroátomo seleccionado entre oxígeno, azufre y nitrógeno, y donde dicho carbono está opcionalmente mono-, di- o tri-substituido con halo, estando dicho carbono opcionalmente mono-substituido con hidroxi, estando dicho carbono opcionalmente mono-substituido con oxo o nitrógeno, estando dicho azufre opcionalmente mono- o di- substituido con oxo, estando dicho nitrógeno opcionalmente mono- o di-substituido con hidrógeno u oxo, y estando dicha cadena carbonada mono, di-, o tri-substituida con V en C4a o en el carbono R3 adyacente a C4a; siempre que en R3, cuando J es carbono, sea distinto de C4a que está opcionalmente reemplazado con un heteroátomo; y siempre que en R3, cuando J es nitrógeno, sea distinto de C4a que está opcionalmente reemplazado con un heteroátomo y sea distinto de C4a que está opcionalmente mono-substituido con hidroxi o nitrógeno; donde V es un anillo parcialmente saturado, totalmente saturado o totalmente insaturado de tres a ocho miembros, que tiene opcionalmente de uno a cuatro heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno tal que V no es imidazolilo o un anillo heterocíclico totalmente saturado que contiene nitrógeno donde el nitrógeno del anillo está unido al grupo R3; un anillo bicíclico que consta de dos anillos condensados de tres a seis miembros, parcialmente saturados, totalmente saturados o totalmente insaturados, tomados independientemente, que tienen opcionalmente de uno a cuatro heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno; o un anillo tricíclico que consiste de tres anillos condensados de tres a seis miembros, parcialmente saturados, totalmente saturados o totalmente insaturados, tomados independientemente, que tienen opcionalmente de uno a cuatro heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno; y dicho substituyente V está opcionalmente mono-, di-, tri-, tetra- o penta-substituido independientemente con V1, alquil C1-6-V1, C(O)-V1, O-alquil C0-6-V1, alquil C1-6-O-V1, C(O)-mono-N- o di- N,N-alquil C1-6-V1, halo, alquilo C1-6, alquenilo C2-6, hidroxi, alcoxi C1-6, alquiltio C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, mono-N- o di-N,N-alquilsulfonilo C1-6, amino, nitro, ciano, oxo, carboxamoilo, mono-N- o di-N,N- alquilcarboxamoilo C1-6, carboxi, alquiloxicarbonilo C1-6, mono-N- o di-N,N-alquilamino C1-6, donde dicho substituyente alquilo C1-6 o alquenilo C2-6 está opcionalmente mono-, di- o tri-substituido independientemente con hidroxi, alcoxi C1-6, alquiltio C1-4, amino, nitro, ciano, oxo, carboxi, alquiloxicarbonilo C1-6, mono-N- o di-N,N-alquilamino C1-6, donde cada uno de los substituyentes alquilo C1-6, alcoxi C1-6, alquiltio C1-4, alquilsulfonilo C1-4 o alquenilo C2-6 también están opcionalmente substituidos con uno a nueve átomos de flúor; donde V1 es un anillo de tres a seis miembros, parcialmente saturado, totalmente saturado o totalmente insaturado, que tiene opcionalmente de uno a dos heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno, o un anillo bicíclico que consta de dos anillos condensados de tres a seis miembros, parcialmente saturados, totalmente saturados o totalmente insaturados, tomados independientemente, que tienen opcionalmente de uno a cuatro heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno; y dicho substituyente V1 está opcionalmente mono-, di-, tri-, tetra- o penta-substituido independientemente con halo, alquilo C1-6, alcoxi C1-6, hidroxi, oxo, amino, nitro, ciano, alquiloxicarbonilo C1-6, mono-N- o di-N,N-alquilamino C1-6 donde dicho substituyente alquilo C1-6 está opcionalmente mono-substituido con oxo, dicho substituyente alquilo C1-6 o alcoxi C1-6 también están opcionalmente substituidos con uno a nueve átomos de flúor; y cada uno de R4, R5, R6 y R7 es independientemente hidrógeno, un enlace, nitro o halo donde dicho enlace está substituido con T o una cadena carbonada, parcialmente saturada, totalmente saturada o totalmente insaturada (C1-12), lineal o ramificada donde cada carbono puede reemplazarse opcionalmente con uno o dos heteroátomos por cadena carbonada donde los heteroátomos se seleccionan independientemente entre oxígeno, azufre y nitrógeno, donde dicho carbono está opcionalmente mono-, di- o tri-substituido independientemente con halo, estando dicho carbono opcionalmente mono-substituido con hidroxi, estando dicho carbono opcionalmente mono-substituido con oxo o nitrógeno, estando dicho azufre opcionalmente mono- o di-substituido con oxo, estando dicho nitrógeno opcionalmente mono- o di-substituido con hidrógeno u oxo, y estando dicha cadena
ARP040101024A 2003-03-28 2004-03-26 Compuestos de quinolina y quinoxalina AR044507A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45827403P 2003-03-28 2003-03-28

Publications (1)

Publication Number Publication Date
AR044507A1 true AR044507A1 (es) 2005-09-14

Family

ID=33098266

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101024A AR044507A1 (es) 2003-03-28 2004-03-26 Compuestos de quinolina y quinoxalina

Country Status (25)

Country Link
EP (1) EP1622872A1 (es)
JP (1) JP2006521344A (es)
KR (1) KR100729883B1 (es)
CN (1) CN1795177A (es)
AR (1) AR044507A1 (es)
AU (1) AU2004224082A1 (es)
BR (1) BRPI0408897A (es)
CA (1) CA2520405A1 (es)
CL (1) CL2004000639A1 (es)
EA (1) EA200501376A1 (es)
EC (1) ECSP056040A (es)
GT (1) GT200400050A (es)
HR (1) HRP20050859A2 (es)
MA (1) MA27828A1 (es)
MX (1) MXPA05010456A (es)
NL (1) NL1025839C2 (es)
NO (1) NO20054989L (es)
OA (1) OA13153A (es)
PA (1) PA8598901A1 (es)
PE (1) PE20050389A1 (es)
TN (1) TNSN05243A1 (es)
TW (1) TWI285641B (es)
UY (1) UY28243A1 (es)
WO (1) WO2004085401A1 (es)
ZA (1) ZA200507819B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ540612A (en) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
ES2887054T3 (es) 2003-04-11 2021-12-21 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
EA010023B1 (ru) 2003-07-14 2008-06-30 Арена Фармасьютикалз, Инк. Конденсированные арильные и гетероарильные производные в качестве модуляторов метаболизма и для профилактики и лечения расстройств, связанных с нарушением метаболизма
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
WO2006033004A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds as cetp inhibitors
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2006091674A1 (en) * 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7888376B2 (en) * 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
UY30118A1 (es) * 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
US7745477B2 (en) * 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
MX2008014284A (es) 2006-05-10 2008-11-18 Novartis Ag Derivados biciclicos como inhibidores de cetp.
US20080305169A1 (en) * 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
JP4108729B2 (ja) * 2006-05-26 2008-06-25 日本たばこ産業株式会社 窒素含有縮合環化合物含有医薬組成物
CN101600708A (zh) * 2006-11-15 2009-12-09 诺瓦提斯公司 有机化合物
JP4846769B2 (ja) * 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
WO2009029632A1 (en) 2007-08-27 2009-03-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
KR101368097B1 (ko) 2008-10-29 2014-03-06 에프. 호프만-라 로슈 아게 신규한 페닐 아마이드 또는 피리딜 아마이드 유도체 및 ｇｐｂａｒ1 작용제로서 이들의 용도
US8420647B2 (en) * 2010-01-21 2013-04-16 Hoffmann-La Roche Inc. 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
HUE053645T2 (hu) 2013-11-18 2021-07-28 Forma Therapeutics Inc Tetrahidrokinolin kompozíciók mint BET bromodomén inhibitorok
WO2015074081A1 (en) 2013-11-18 2015-05-21 Bair Kenneth W Benzopiperazine compositions as bet bromodomain inhibitors
WO2015134711A1 (en) 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
CN108348527A (zh) 2015-10-30 2018-07-31 Ptc医疗公司 用于治疗癫痫的方法
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
CN110452183B (zh) * 2019-09-04 2023-03-14 中国科学院上海有机化学研究所 一种手性杂环化合物的制备方法
CN111440162A (zh) * 2020-04-01 2020-07-24 邱曲真 噻唑二氢萘类衍生物及其在代谢性疾病中的应用
CN114656406B (zh) * 2022-01-25 2023-09-05 阿里生物新材料（常州）有限公司 一种2-氟代嘧啶-4-羧酸的合成方法
CN115894358B (zh) 2022-10-25 2025-05-27 广东省农业科学院蚕业与农产品加工研究所 一种具有脂肪酶抑制活性的米糠生物碱、药物组合物及其制备方法和应用
WO2025111184A1 (en) * 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE351464C (de) * 1917-12-18 1922-04-07 Chemische Werke Grenzach Aktie Verfahren zur Darstellung von Derivaten einer hydrierten 2-Phenylchinolin-4-carbonsaeure
HUT78117A (hu) * 1994-12-22 1999-11-29 Ligand Pharmaceuticals Incorporated Szteroid receptor modulátor kinolin- és kondenzált kinolinszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
CA2270123A1 (en) * 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
AU2717899A (en) * 1998-01-26 1999-08-09 Smithkline Beecham Plc Quinoline derivatives as antibacterials
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5271716A1 (es) * 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida

Also Published As

Publication number Publication date
AU2004224082A1 (en) 2004-10-07
CN1795177A (zh) 2006-06-28
CL2004000639A1 (es) 2005-02-04
ZA200507819B (en) 2007-04-25
KR100729883B1 (ko) 2007-06-18
OA13153A (en) 2006-12-13
KR20050115938A (ko) 2005-12-08
EP1622872A1 (en) 2006-02-08
WO2004085401A1 (en) 2004-10-07
CA2520405A1 (en) 2004-10-07
PA8598901A1 (es) 2004-11-26
JP2006521344A (ja) 2006-09-21
HRP20050859A2 (en) 2006-02-28
ECSP056040A (es) 2006-01-27
GT200400050A (es) 2005-03-02
MXPA05010456A (es) 2006-03-21
TNSN05243A1 (fr) 2007-06-11
PE20050389A1 (es) 2005-05-30
UY28243A1 (es) 2004-11-08
NO20054989D0 (no) 2005-10-26
TW200508222A (en) 2005-03-01
WO2004085401A8 (en) 2005-12-01
MA27828A1 (fr) 2006-04-03
TWI285641B (en) 2007-08-21
BRPI0408897A (pt) 2006-04-18
NO20054989L (no) 2005-12-16
NL1025839C2 (nl) 2006-09-06
EA200501376A1 (ru) 2006-04-28
NL1025839A1 (nl) 2004-09-30

Similar Documents

Publication Publication Date Title
AR044507A1 (es) Compuestos de quinolina y quinoxalina
AR030523A1 (es) Compuestos 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-amino sustituidas, su uso en la preparacion de medicamentos, composiciones farmaceuticas, y equipo que los contiene.
CO5370678A1 (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas
AR086837A1 (es) Moduladores heterociclicos de sintesis lipidica
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
AR106652A1 (es) Compuestos para tratar la esclerosis lateral amiotrófica
MX2015007883A (es) Compuestos para protección de células.
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
MX2012008049A (es) Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
CO6160237A2 (es) Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden
MX2010000658A (es) Derivados de pirimidina 934.
CO5700824A2 (es) Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen
RU2009148796A (ru) Производные пиперидина/пиперазина
MX2008001395A (es) Inhibidores macrociclicos del virus de la hepatitis c.
CO5150220A1 (es) 4-carboxiamino-2- metil-1,2,3,4-tetrahidroquinolinas
AR072008A1 (es) Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
PE20160608A1 (es) Compuestos de quinolina selectivamente sustituida
PE20141059A1 (es) Indazoles
PA8783601A1 (es) Derivados de piperidina/piperazina
AR036365A1 (es) 1,8-naftiridin-4(1h)-onas alquin-aril sustituidas y composiciones farmaceuticas que las contienen
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
IL181271A0 (en) Triazolophthalazine derivatives and pharmaceutical compositions containing the same
AR059802A1 (es) Compuestos y derivados de dibencilamina, combinaciones y composiciones farmaceuticas que los comprenden y el uso de estos derivados en el tratamiento de enfermedades mediadas por la actividad de cetp.
MX347476B (es) Compuestos de ácido dimetil-benzoico.
UY30787A1 (es) "inhibidores benzoimidazolicos de trpv1"

Legal Events

Date Code Title Description
FB Suspension of granting procedure